ResearchAndMarkets.com has added a report assessing SOMATULINE (lanreotide) across the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. The analysis covers historical performance from 2020, current market dynamics and sales forecasts through 2034, including SOMATULINE’s clinical profile, regulatory history, commercial positioning, pricing, reimbursement and competitive environment. SOMATULINE is approved for acromegaly, unresectable or metastatic well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome. The long-acting somatostatin analog has high affinity for somatostatin receptor subtypes 2 and 5 and is supplied in a ready-to-use prefilled syringe for deep subcutaneous injection, typically every four weeks. The report cites the CLARINET trial, guideline support, more than two decades of clinical experience and the potential for home administration as factors supporting continued use. Ipsen reported 4.3% sales growth at constant exchange rates in fiscal year 2025 and indicated expectations for continued growth in 2026, despite generic lanreotide competition. The analysis also examines safety, investigational and off-label research, emerging therapies, market access, clinical trials, patents, commercial partnerships and regional treatment costs. It identifies generic competition, pricing pressure, changing guidelines and new therapies as factors that could shape SOMATULINE’s performance through 2034.